|
|
Vaccine Detail
|
Hodgkin's antigens-GM-CSF-expressing cell vaccine |
| Vaccine Information |
- Vaccine Name: Hodgkin's antigens-GM-CSF-expressing cell vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: Hodgkin's antigens (NCT00478062; NCIT_C61592)
- Immunization Route: Other
- Description: This is an allogeneic vaccine consisting of Hodgkin lymphoma cells transfected with the granulocyte macrophage-colony-stimulating factor (GM-CSF) gene with potential antineoplastic activity. Hodgkin antigens-GM-CSF-expressing cell vaccine may stimulate a cytotoxic T-lymphocyte (CTL) immune response against Hodgkin lymphoma-associated antigens, which may result in the lysis of tumor cells expressing these antigens. Also, transfected Hodgkin lymphoma cells secrete GM-CSF, which may potentiate the CTL response against Hodgkin lymphoma-associated antigens. (NCIT_C61592) Vaccines made from a tumor antigen may help the body build an effective immune response to kill tumor cells. This vaccine contains cells expressing Hodgkin's antigens and GM-CSF, and could cause an immunological response in Hodgkin's lymphoma patients. (NCT00478062)
|
| Host Response |
|
|
| References |
NCIT_C61592: Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61592]
NCT00478062: Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma [https://clinicaltrials.gov/study/NCT00478062]
|
|
